PUBLISHER: The Business Research Company | PRODUCT CODE: 1643992
PUBLISHER: The Business Research Company | PRODUCT CODE: 1643992
Lyophilized Injectable Drugs Global Market Opportunities And Strategies To 2033
Lyophilized injectable drugs are pharmaceutical formulations processed through lyophilization, a freeze-drying technique that removes water or solvent under low temperature and pressure. This method ensures the stability of active pharmaceutical ingredients (APIs) that might otherwise degrade in liquid form. Lyophilization is widely used for drugs requiring a long shelf life, especially biologics like monoclonal antibodies, vaccines and enzymes, which are sensitive to environmental conditions.
The lyophilized injectable drugs market consists of sales, by entities (organizations, sole traders and partnerships), of freeze-dried pharmaceutical formulations reconstituted for injection, including biologics, vaccines and small molecule drugs.
The global lyophilized injectable drugs market was valued at $3,442.00 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 2.00%.
Increasing Demand For Personalized Medicine
The increasing demand for personalized medicine propelled the growth of the lyophilized injectable drugs market. Personalized medicine, also known as precision medicine or individualized medicine, is an approach to medical care that aims to tailor treatments and interventions to the specific characteristics of each patient. The shift toward personalized medicine increased demand for customized biopharmaceuticals. Lyophilization became essential for preserving biologic or biotechnology-based treatments therapies, by enhancing their stability and shelf life. This process ensures that personalized treatments remain effective during distribution and storage, thus driving the growth of lyophilization services to meet the needs of advanced, patient-specific therapies. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, estimated that more than 75,000 genetic testing products and 300 personalized medicines were on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, according to the Personalized Medicine Coalition (PMC), personalized medicines accounted for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, increasing demand for personalized medicine supported the growth of the lyophilized injectable drugs market during the historic period.
Focus On Launch Of In Glass Prefillable Syringes For Lyophilized Drugs
Major companies operating in the lyophilized injectable drugs market are focused on the development advanced products, such as a glass prefillable syringe, for meeting patient needs. The glass prefillable syringe is a specialized injection system for lyophilized injectable drugs, ensuring accurate delivery and preserving the stability of biologic formulations. In September 2024, Becton, Dickinson and Company, US-based pharmaceutical company, launched BD Neopak XtraFlow. This advanced syringe is specifically designed to enhance the subcutaneous administration of biologic drugs, particularly those with higher viscosity, which often includes lyophilized formulations. It is equipped with an 8-millimeter needle and a thinner wall cannula, reducing both the injection force and time, which enhances user comfort for both patients and healthcare providers. This syringe is part of BD's commitment to meeting the increasing demand for biologic therapies, providing pharmaceutical developers with a solution that effectively handles challenging drug viscosities while streamlining the injection process.
The global lyophilized injectable drugs market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 22.77% of the total market in 2023.
Lyophilized Injectable Drugs Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global lyophilized injectable drugs market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
The report covers the following chapters
Markets Covered:
Table of Contents
1 Executive Summary
- 1.1 Lyophilized Injectable Drugs - Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Lyophilized Injectable Drugs Market Definition And Segmentations
- 6.4 Market Segmentation By Packaging Type
7 Major Market Trends
8 Lyophilized Injectable Drugs Market - Macro-Economic Scenario
9 Global Market Size And Growth
10 Global Lyophilized Injectable Drugs Market Segmentation
11 Lyophilized Injectable Drugs Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape And Company Profiles
20 Other Major And Innovative Companies
21 Competitive Benchmarking
22 Competitive Dashboard
23 Key Mergers And Acquisitions
24 Opportunities And Strategies
25 Lyophilized Injectable Drugs Market, Conclusions And Recommendations
26 Appendix
